Effect of vascular endothelial growth factor and its receptor inhibitor on proliferation and invasion in bladder cancer

Urologia Internationalis

Volumn 83, Issue 1, 2009, Pages 98-106

  Nakanishi, Ryoichi ^a   Oka, Natsuo ^a   Nakatsuji, Hiroyoshi ^a   Koizumi, Takahiro ^a   Sakaki, Manabu ^a   Takahashi, Masayuki ^a   Fukumori, Tomoharu ^a   Kanayama, Hiro Omi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Bladder cancer; Vascular endothelial growth factor; Vascular endothelial growth factor receptor

Indexed keywords

BEVACIZUMAB; COMPLEMENTARY DNA; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT VASCULOTROPIN; RNA; SU 1498; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLOOD LEVEL; CANCER CELL CULTURE; CANCER INVASION; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERUM; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CINNAMATES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 68549125346     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000224877     Document Type: Article

References (35)

1. Jamel A, Murray T, Ward E, Samuels A, Tiwari RC, Ghaffor A, Feuer EJ, Thun MJ: Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Saxman SB, Propert KJ, Einhorn LH: Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine and doxoru-bicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997;15:2564-2569.
3. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
4. Ferrar N, Gerber HP, LeCourter J: The biology of VEGF and its receptors. Nat Med 2003;9:669-676.
5. Yang CC, Chu KC, Yeh WM: The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression. Urol Oncol 2004;22:1-6.
6. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, Senger DR: Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pat hol 1993;143 :1255-1262.
7. Crew JP, O'Brien T, Bradburn M, Fuggle S, Bicknell R, Cranston D, Harris AL: Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 1997;57:5281-5285.
8. Ioachim E, Michael M, Salmas M, Michael MM, Stavropoulos NE, Malamou-Mitsi V: Hypoxia-inducible factors HIF-1alpha and HIF-2alpha expression in bladder cancer and their associations with other angiogenesis-related proteins. Urol Int 2006;77:255-263.
9. Gravas S, Bosinakou I, Kehayas P, Giannopoulos A: Urinary basic fibroblast growth factor in bladder cancer patients: his-topathological correlation and clinical potential. Urol Int 2004;73:173-177.
10. Ferrara N: The role of vascular endothelial growth factor in the regulation of blood vessel growth; in Bicknell R, Lewis CE, Ferrara N (eds): Tumor Angiogenesis. New York, Oxford University Press, 1997.
11. Hong X, Jiang F, Kalkanis SN, Zhang ZG, Zhang X P, DeCarvalho AC, Katakowski M, Bobbitt K, Mikkelsen T, Chopp M: SDF-1and CXCR-4are up-regulated by VEGF and contribute to glioma cell invasion. Cancer Lett 2005;236:39-45.
12. Bachelder RE, Wendt MA, Mercurio AM: Vascu lar endot helial grow t h factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res 2002;62:7203-7206.
13. Wey JS, Fan F, Gray MJ, Bauer TW, McCarty MF, Somcio R, Liu W, Evans DB, Wu Y, Hicklin DJ, Ellis LM: Vascular endothelial growth factor receptor-1promotes migration and invasion in pancreatic carcinoma cell lines. Cancer 2005;104:427-438.
14. Wang FQ, So J, Reierstad S, Fishman DA: Vascular endothelial growth factor-regulated ovarian cancer invasion and migration involves expression and activation of matrix metalloproteinases. Int J Cancer 2006;118:879-888.
15. Qi L, Robinson WA, Brady BM, Glode LM: Migration and invasion of human prostate cancer cells is related to expression of VEGF and its receptors. Anticancer Res 2003;23:3917-3922.
16. Ferrer FA, Miller LJ, Lindquist R, Kowalczyk P, Laudone VP, Albertsen PC, Kreutzer DL: Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 1999;54:567-572.
17. Decaussin M, Sartelet H, Robert C, Moro D, Claraz C, Brambilla C, Brambilla E: Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1and VEGF-R2-Flk1/KDR) in non-small cell lung carcinoma (NSCLCs): correlation with angiogenesis and survival. J Pathol 1999;188:369-377.
18. Zhang H, Wu J, Meng L, Shou CC: Expression of vascular endothelial growth factor and its receptors KDR and Flt-1in gastric cancer cells. World J Gastroenterol 2002;8:994-998.
19. Boocock CA, Charnock-Jones DS, Sharkey AM, McLaren J, Barker PJ, Wright KA, Twentyman PR, Smith SK: Expression of vascular endothelial growth factor and its receptors Flt and KDR in ovarian carcinoma. J Natl Cancer Inst 1995;87:506-516.
20. Graeven U, Fieldler W, Karpinski S, Ergün S, Kilic N, Rodeck U, Schmiegel W, Hossfeld DK: Melanoma-associated expression of vascular endothelial growth factor and its receptors FLT-1and KDR. J Cancer Res Clin Oncol 1999;125:621-629.
21. Wu W, Shu X, Hovsepyan H, Mosteller RD, Broek D: VEGF receptor expression and signaling in human bladder tumors. Oncogene 2003;22:3361-3370.
22. Matsumori Y, Yano S, Goto H, Nakataki E, Wedge SR, Ryan AJ, Sone S: ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model. Oncol Res 2006;16:15-26.
23. Masood R, Cai J, Zheng T, Smith DL, Hinton DR, Gill PS: Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 2001;98:1904-1913.
24. Jacobsen J, Rasmuson T, Grank v ist K, Ljung-berg B: Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000;163:343-347.
25. Linderholm B, Tavelin B, Grankvist K, Hen-riksson R: Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol 1998;16:3121-3128.
26. Salven P, Ruotsalainen T, Mattson K, Joensuu H: High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer 1998;79:144-146.
27. Mitra AP, Datar RH, Cote RJ: Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol 2006;24:5552-5564.
28. Mitra AP, Lin H, Datar RH, Cote RJ: Molecular biology of bladder cancer: prognostic and clinical implications. Clin Genitourin Ca ncer 2006;5:67-77.
29. Pepper MS, Ferrara N, Orci L, Montesano R: Vascular endothelial growth factor (VEGF) induces plasminogen activators and plas-minogen activator inhibitor-1in microvas-cular endothelial cells. Biochem Biophys Res Commun 1991;181:902-906.
30. Lipponen P, Eskelinen M: Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer 1994;69:1120-1125.
31. Ravery V, Colombel M, Popov Z, Bastuji S, Patard JJ, Bellot J, Abbou CC, Fradet Y, Chopin DK: Prognostic value of epidermal growth factor-receptor, T138and T43 expression in bladder cancer. Br J Cancer 1995;71:196-200.
32. Krüger S, Weitsch G, Büttner H, Matthiensen A, Böhmer T, Ma rquardt T, Sayk F, Feller AC, Böhle A: HER2overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int J Cancer 2002;102:514-518.
33. Motzer RJ, Hutson TE, Tomczak P, Michael-son MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-124.
34. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwar tz B, Shan M, Simantov R, Bukowski RM, TARGET Study Group: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134.
35. Froehner M, Hakenberg OW, Wirth MP: Molecular therapy in urologic oncology. Urol Int 2007;79:1-7.